FIBRICOR (Page 6 of 7)

14.2 Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia

The effects of fenofibrate at doses equivalent to 105 mg of FIBRICOR were assessed from four randomized, placebo-controlled, double-blind, parallel-group studies including patients with the following mean baseline lipid values: Total-C 306.9 mg/dL; LDL-C 213.8 mg/dL; HDL-C 52.3 mg/dL; and triglycerides 191.0 mg/dL. Fenofibrate therapy lowered LDL-C, Total-C, and the LDL-C/HDL-C ratio. Fenofibrate therapy also lowered triglycerides and raised HDL-C (see Table 5).

Table 5. Mean Percent Change in Lipid Parameters at End of Fenofibrate Treatment *
Treatment Group Total-C LDL-C HDL-C TG
Duration of study treatment was 3 to 6 months.
p = < 0.05 vs. Placebo
Pooled Cohort
Mean baseline lipid values (n=646) 306.9 mg/dL 213.8 mg/dL 52.3 mg/dL 191.0 mg/dL
All FEN (n=361) -18.7% -20.6% +11.0% -28.9%
Placebo (n=285) -0.4% -2.2% +0.7% +7.7%
Baseline LDL-C >160 mg/dL and TG <150 mg/dL (Type IIa)
Mean baseline lipid values (n=334) 307.7 mg/dL 227.7 mg/dL 58.1 mg/dL 101.7 mg/dL
All FEN (n=193) -22.4% -31.4% +9.8% -23.5%
Placebo (n=141) +0.2% -2.2% +2.6% +11.7%
Baseline LDL-C >160 mg/dL and TG ≥150 mg/dL (Type IIb)
Mean baseline lipid values (n=242) 312.8 mg/dL 219.8 mg/dL 46.7 mg/dL 231.9 mg/dL
All FEN (n=126) -16.8% -20.1% +14.6% -35.9%
Placebo (n=116) -3.0% -6.6% +2.3% +0.9%

In a subset of the subjects, measurement of Apo B was conducted. Fenofibrate treatment significantly reduced Apo B from baseline to endpoint as compared with placebo (-25.1% vs. 2.4%, p < 0.0001, n=213 and 143 respectively).

The effect of FIBRICOR on cardiovascular morbidity and mortality has not been determined.


FIBRICOR® (fenofibric acid) Tablets 35 mg, are white, round tablets, debossed “AR 787” on one side and blank on the other side.

Bottles of 30 NDC 71511-501-30

FIBRICOR® (fenofibric acid) Tablets 105 mg, are white, modified oval tablets, debossed “AR 788” on one side and blank on the other side.

Bottles of 30 NDC 71511-502-30

Store at USP controlled room temperature 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)



Patients should be advised:

  • of the potential benefits and risks of FIBRICOR.
  • not to use FIBRICOR if there is a known hypersensitivity to fenofibrate or fenofibric acid.
  • that if they are taking coumarin anticoagulants, FIBRICOR may increase their anticoagulant effect, and increased monitoring may be necessary.
  • of medications that should not be taken in combination with FIBRICOR.
  • to continue to follow an appropriate lipid-modifying diet while taking FIBRICOR.
  • to take FIBRICOR once daily, without regard to food, at the prescribed dose, swallowing each tablet whole.
  • to inform their physician of all medications, supplements, and herbal preparations they are taking and any change to their medical condition. Patients should also be advised to inform their physicians prescribing a new medication that they are taking FIBRICOR.
  • to inform their physician of any muscle pain, tenderness, or weakness; onset of abdominal pain; or any other new symptoms.
  • to return to their physician’s office for routine monitoring.
  • not to breastfeed during treatment with FIBRICOR and for 5 days after the final dose.

TriCor® is a registered trademark of Abbott Laboratories.

FIBRICOR® is a registered U.S. trademark of Athena Bioscience LLC

U.S. Patent Nos. 7,569,612; 7,741,373; 7,741,374; and 7,915,247.

Manufactured for: Athena Bioscience LLC
Athens, GA 30601

Revised: 12/2020

Reference ID: 4433499

All resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.